0954.HK
Changmao Biochemical Engineering Company Limited [0954.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0954.HK Stock Summary
In the News
0954.HK Financial details
Company Rating
Buy
Market Cap
219.73M
Income
44.7M
Revenue
643.83M
Book val./share
1.4
Cash/share
0.21
Dividend
0.09
Dividend %
16.06%
Employees
631
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
3.52
Forward P/E
-
PEG
-1.51
P/S
0.39
P/B
0.37
P/C
1.9
P/FCF
-1.4
Quick Ratio
0.23
Current Ratio
1.32
Debt / Equity
0.56
LT Debt / Equity
0.18
-
-
EPS (TTM)
0.08
EPS next Y
-
EPS next Q
-
EPS this Y
36.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
9.47%
Revenue last 5Y
2.7%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
7%
ROE
11%
ROC
0.1%
Gross Margin
25%
Oper. Margin
12%
Profit Margin
11%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.36-1.15
52W High
-
52W Low
-
RSI
46
Rel Volume
9
Avg Volume
300.75K
Volume
2.71M
Perf Week
0%
Perf Month
-24.53%
Perf Quarter
-
Perf Half Y
-25.93%
-
-
-
-
Beta
0.63
-
-
Volatility
0.01%, 0.04%
Prev Close
2.56%
Price
0.4
Change
5.26%
0954.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.21 | 0.93 | 0.84 | 1.03 | 1.38 | |
| Net income per share | 0.1 | 0.11 | 0.03 | 0.11 | 0.15 | |
| Operating cash flow per share | 0.08 | 0.22 | 0.11 | -0.01 | 0.04 | |
| Free cash flow per share | 0.02 | 0.15 | -0.04 | -0.49 | -0.38 | |
| Cash per share | 0.17 | 0.23 | 0.25 | 0.11 | 0.12 | |
| Book value per share | 1.19 | 1.25 | 1.23 | 1.32 | 1.47 | |
| Tangible book value per share | 1.14 | 1.25 | 1.18 | 1.13 | 1.29 | |
| Share holders equity per share | 1.19 | 1.25 | 1.23 | 1.32 | 1.47 | |
| Interest debt per share | 0.08 | 0.04 | 0 | 0.17 | 0.56 | |
| Market cap | 357.91M | 402.02M | 262.99M | 293.97M | 327.44M | |
| Enterprise value | 312.12M | 303.26M | 129.45M | 324.6M | 558.95M | |
| P/E ratio | 7.08 | 6.9 | 15.63 | 5.04 | 4.02 | |
| Price to sales ratio | 0.56 | 0.81 | 0.59 | 0.54 | 0.45 | |
| POCF ratio | 8.05 | 3.4 | 4.46 | -42.37 | 16.68 | |
| PFCF ratio | 30.92 | 5.22 | -12.67 | -1.13 | -1.61 | |
| P/B Ratio | 0.57 | 0.61 | 0.4 | 0.42 | 0.42 | |
| PTB ratio | 0.57 | 0.61 | 0.4 | 0.42 | 0.42 | |
| EV to sales | 0.49 | 0.61 | 0.29 | 0.59 | 0.77 | |
| Enterprise value over EBITDA | 3.46 | 3.02 | 2.58 | -31.54 | 4.36 | |
| EV to operating cash flow | 7.02 | 2.56 | 2.2 | -46.78 | 28.47 | |
| EV to free cash flow | 26.96 | 3.94 | -6.23 | -1.25 | -2.74 | |
| Earnings yield | 0.14 | 0.15 | 0.06 | 0.2 | 0.25 | |
| Free cash flow yield | 0.03 | 0.19 | -0.08 | -0.88 | -0.62 | |
| Debt to equity | 0.06 | 0.03 | 0 | 0.13 | 0.37 | |
| Debt to assets | 0.05 | 0.03 | 0 | 0.09 | 0.24 | |
| Net debt to EBITDA | -0.51 | -0.98 | -2.66 | -2.98 | 1.81 | |
| Current ratio | 3.15 | 4.25 | 2.08 | 1.23 | 1.32 | |
| Interest coverage | 48.26 | 120.56 | 274.18 | -19.65 | 33.49 | |
| Income quality | 0.81 | 1.89 | 3.43 | -0.08 | 0.22 | |
| Dividend Yield | 0 | 0.07 | 0.11 | 0.04 | 0 | |
| Payout ratio | 0 | 0.45 | 1.73 | 0.18 | 0 | |
| Sales general and administrative to revenue | 0.1 | 0.12 | 0.16 | 0.13 | 0.12 | |
| Research and developement to revenue | 0 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.04 | 0 | 0.03 | 0.1 | 0.08 | |
| Capex to operating cash flow | -0.74 | -0.35 | -1.35 | 36.35 | -11.38 | |
| Capex to revenue | -0.05 | -0.08 | -0.18 | -0.46 | -0.31 | |
| Capex to depreciation | -0.96 | -1.17 | -2.43 | -8.63 | -6.94 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.6 | 1.76 | 0.94 | 1.81 | 2.25 | |
| ROIC | 0.08 | 0.09 | 0.03 | -0.03 | 0.08 | |
| Return on tangible assets | 0.07 | 0.08 | 0.02 | 0.07 | 0.07 | |
| Graham Net | 0.08 | 0.28 | 0.1 | -0.14 | -0.43 | |
| Working capital | 212.69M | 237.61M | 212.88M | 60.31M | 88.03M | |
| Tangible asset value | 604.26M | 661.74M | 624.32M | 601.15M | 684.87M | |
| Net current asset value | 210.25M | 235.28M | 211.8M | 58.04M | -65.82M | |
| Invested capital | 0.06 | 0.03 | 0 | 0.13 | 0.37 | |
| Average receivables | 3.78M | 33.92M | 66.83M | 78.69M | 81.63M | |
| Average payables | 46.64M | 19.96M | 49.42M | 87.26M | 81.17M | |
| Average inventory | 111.68M | 107.1M | 115.86M | 124.22M | 141.91M | |
| Days sales outstanding | 2.11 | 47.33 | 57.15 | 58.51 | 37.71 | |
| Days payables outstanding | 14.17 | 20.45 | 84.23 | 68.66 | 44.22 | |
| Days of inventory on hand | 77.4 | 107.83 | 134.35 | 88.08 | 106.94 | |
| Receivables turnover | 172.74 | 7.71 | 6.39 | 6.24 | 9.68 | |
| Payables turnover | 25.75 | 17.85 | 4.33 | 5.32 | 8.25 | |
| Inventory turnover | 4.72 | 3.38 | 2.72 | 4.14 | 3.41 | |
| ROE | 0.08 | 0.09 | 0.03 | 0.08 | 0.1 | |
| Capex per share | -0.06 | -0.08 | -0.15 | -0.48 | -0.42 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.36 | 0.33 | 0.33 | 0.28 | 0.28 | |
| Net income per share | 0.04 | 0.04 | 0.04 | 0 | 0 | |
| Operating cash flow per share | 0.02 | 0 | 0 | -0.02 | -0.02 | |
| Free cash flow per share | -0.09 | -0.1 | -0.1 | -0.09 | -0.09 | |
| Cash per share | 0.23 | 0.12 | 0.12 | 0.21 | 0.21 | |
| Book value per share | 1.39 | 1.47 | 1.47 | 1.4 | 1.4 | |
| Tangible book value per share | 1.39 | 1.47 | 1.29 | 1.4 | 1.4 | |
| Share holders equity per share | 1.39 | 1.47 | 1.47 | 1.4 | 1.4 | |
| Interest debt per share | 0.46 | 0.29 | 0.55 | 0.25 | 0.8 | |
| Market cap | 311.96M | 316.86M | 327.45M | 472.46M | 416.17M | |
| Enterprise value | 443.11M | 256.87M | 558.96M | 372.33M | 731.29M | |
| P/E ratio | 3.82 | 3.91 | 4.04 | 56.83 | 50.06 | |
| Price to sales ratio | 1.63 | 1.83 | 1.89 | 3.19 | 2.81 | |
| POCF ratio | 28.7 | -301.06 | -311.12 | -46.35 | -40.83 | |
| PFCF ratio | -6.36 | -5.99 | -6.19 | -10.1 | -8.9 | |
| P/B Ratio | 0.42 | 0.41 | 0.42 | 0.64 | 0.56 | |
| PTB ratio | 0.42 | 0.41 | 0.42 | 0.64 | 0.56 | |
| EV to sales | 2.32 | 1.48 | 3.22 | 2.51 | 4.93 | |
| Enterprise value over EBITDA | 14.38 | 9.3 | 20.25 | 27.56 | 54.13 | |
| EV to operating cash flow | 40.77 | -244.06 | -531.08 | -36.52 | -71.74 | |
| EV to free cash flow | -9.03 | -4.86 | -10.57 | -7.96 | -15.64 | |
| Earnings yield | 0.07 | 0.06 | 0.06 | 0 | 0 | |
| Free cash flow yield | -0.16 | -0.17 | -0.16 | -0.1 | -0.11 | |
| Debt to equity | 0.33 | 0.2 | 0.37 | 0.18 | 0.56 | |
| Debt to assets | 0.21 | 0.13 | 0.24 | 0.11 | 0.33 | |
| Net debt to EBITDA | 4.25 | -2.17 | 8.39 | -7.41 | 23.33 | |
| Current ratio | 1.68 | 1.32 | 1.32 | 0.97 | 0.97 | |
| Interest coverage | 0 | 0 | 16.43 | 0 | 0.45 | |
| Income quality | 0.53 | -0.05 | -0.05 | -4.9 | -4.9 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.11 | 0.14 | 0.14 | 0.11 | 0.11 | |
| Research and developement to revenue | 0 | 0.04 | 0.04 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.08 | 0 | 0 | |
| Capex to operating cash flow | -5.51 | 49.23 | 49.23 | 3.59 | 3.59 | |
| Capex to revenue | -0.31 | -0.3 | -0.3 | -0.25 | -0.25 | |
| Capex to depreciation | -7.58 | -6.32 | -6.32 | -3.44 | -3.44 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.1 | 1.12 | 1.12 | 0.35 | 0.35 | |
| ROIC | 0.02 | 0.02 | 0.02 | 0 | 0 | |
| Return on tangible assets | 0.02 | 0.02 | 0.02 | 0 | 0 | |
| Graham Net | -0.3 | -0.43 | -0.43 | -0.53 | -0.53 | |
| Working capital | 163.53M | 88.03M | 88.03M | -12.03M | -12.03M | |
| Tangible asset value | 737.29M | 778.12M | 684.87M | 741.32M | 741.32M | |
| Net current asset value | -6.52M | -65.82M | -65.82M | -162.08M | -162.08M | |
| Invested capital | 0.33 | 0.2 | 0.37 | 0.18 | 0.56 | |
| Average receivables | 0 | 83.28M | 75.42M | 74.43M | 73.44M | |
| Average payables | 0 | 84.7M | 66.54M | 43.46M | 20.37M | |
| Average inventory | 0 | 142.92M | 160.91M | 166.53M | 172.15M | |
| Days sales outstanding | 42.85 | 39.1 | 39.1 | 44.57 | 44.57 | |
| Days payables outstanding | 63.45 | 46.53 | 46.53 | 14.37 | 14.37 | |
| Days of inventory on hand | 77.07 | 112.52 | 112.52 | 121.45 | 121.45 | |
| Receivables turnover | 2.1 | 2.3 | 2.3 | 2.02 | 2.02 | |
| Payables turnover | 1.42 | 1.93 | 1.93 | 6.26 | 6.26 | |
| Inventory turnover | 1.17 | 0.8 | 0.8 | 0.74 | 0.74 | |
| ROE | 0.03 | 0.03 | 0.03 | 0 | 0 | |
| Capex per share | -0.11 | -0.1 | -0.1 | -0.07 | -0.07 |
0954.HK Frequently Asked Questions
What is Changmao Biochemical Engineering Company Limited stock symbol ?
Changmao Biochemical Engineering Company Limited is a CN stock and trading under the symbol 0954.HK
What is Changmao Biochemical Engineering Company Limited stock quote today ?
Changmao Biochemical Engineering Company Limited stock price is $0.4 today.
Is Changmao Biochemical Engineering Company Limited stock public?
Yes, Changmao Biochemical Engineering Company Limited is a publicly traded company.
Company Profile
- Volume Average 300.75K
- Market Capitalization 219.73M
- Employee 631
- CEO Mr. Chun Pan
- Headquarters Changzhou,CN
- IPO Date 2002-06-28
-
Website
https://www.cmbec.com.hk 
Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally. Its products include fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. The company is also involved in the research and development of medicine and nutraceutical products; production and sale of food additives; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou, the People's Republic of China.
